ArticleAtherosclerosis2012
Acyl chain-dependent effect of lysophosphatidylcholine on cyclooxygenase (COX)-2 expression in endothelial cells.
Article in Atherosclerosis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Ontogeny independent expression of LPCAT2 in granuloma macrophages during experimental visceral leishmaniasis.Communications biology · 2026Article
- Linoleoyl-lysophosphatidylcholine drives non-inflammatory apoptosis in neutrophils via lipid rafts.Frontiers in immunology · 2026Article
- Construction of a lipid metabolism-based prognostic gene signature in cervical squamous cell carcinoma and validation of LIPG's oncogenic role.Cancer cell international · 2025Article
- The Nutritional Gene Expression Regulation Potential of a Lysolecithin-Based Product.Current issues in molecular biology · 2025Article
- Lipidomic profiling of human adiposomes identifies specific lipid shifts linked to obesity and cardiometabolic risk.JCI insight · 2025Article
- Causal Association Between Genetically Predicted Circulating Metabolites and Pressure Ulcers: A Two-Sample Mendelian Randomization Study.Journal of inflammation research · 2025Article
- Comparison of Adiposomal Lipids between Obese and Non-Obese Individuals.Metabolites · 2024Article
- Identification of Plasma Lipid Alterations Associated with Melanoma Metastasis.International journal of molecular sciences · 2024Article
- Multinomial machine learning identifies independent biomarkers by integrated metabolic analysis of acute coronary syndrome.Scientific reports · 2023Article
- Article
- Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice.Frontiers in pharmacology · 2023Article
- Metabolomic Characteristics of Liver and Cecum Contents in High-Fat-Diet-Induced Obese Mice Intervened withFoods (Basel, Switzerland) · 2022Article
- Serum Metabonomics Reveals Risk Factors in Different Periods of Cerebral Infarction in Humans.Frontiers in molecular biosciences · 2021Article
- Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia.Inflammation · 2020Article
- An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System.International journal of molecular sciences · 2020Review
- Effects of Long-Chain Fatty Acyl-CoA Synthetase 1 on Diglyceride Synthesis and Arachidonic Acid Metabolism in Sheep Adipocytes.International journal of molecular sciences · 2020Article
- Diuretic Effect and Metabolomics Analysis of Crude and Salt-Processed Plantaginis Semen.Frontiers in pharmacology · 2020Article
- Broad Lipidomic and Transcriptional Changes of Prophylactic PEA Administration in Adult Mice.Frontiers in neuroscience · 2019Article
- Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Lysophosphatidylcholine induces cyclooxygenase-2-dependent IL-6 expression in human cardiac fibroblasts.Cellular and molecular life sciences : CMLS · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePreviously we identified palmitoyl-, oleoyl- linoleoyl-, and arachidonoyl-lysophosph-atidylcholine (LPC 16:0, 18:1, 18:2 and 20:4) as the most prominent LPC species generated by endothelial lipase (EL). In the present study, we examined the capacity of those LPC to modulate expression of cyclooxygenase (COX)-2 in vascular endothelial cells. METHODS &
resultsLPC 16:0 and 20:4 promoted both COX-2 mRNA- and protein synthesis with different potencies and kinetics. While LPC 18:1 induced a weak and transient increase in COX-2 mRNA, but not protein, LPC 18:2 increased COX-2 protein, without impacting mRNA. Chelation of intracellular Ca(2+) and inhibition of p38 MAPK markedly attenuated 16:0 LPC- and 20:4 LPC- elicited induction of COX-2 expression, whereas inhibition of phospholipase C (PLC) attenuated only the effect of 16:0 LPC. LPC 16:0 and 20:4 differed markedly in their potencies to increase cytosolic Ca(2+) concentration and in the kinetics of p38 MAPK activation. While the effects of 16:0 and 20:4 LPC on COX-2 expression were profoundly sensitive to silencing of either c-Jun or p65 (NF-κB), respectively, silencing of cyclic AMP responsive element binding protein (CREB) attenuated markedly the effect of both LPC.
conclusionOur results indicate that the tested LPC species are capable of inducing COX-2 expression, whereby the efficacy and the relative contribution of underlying signaling mechanisms markedly differ, due to the length and degree of saturation of LPC acyl chains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.